SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

Evrysdi

PTCT·PTC THERAPEUTICS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed since August 2020.
Why 4/10
Evrysdi is an already-approved, marketed drug with no pending PDUFA or pivotal readout. PTC has fully monetized its royalty interest (sold to Royalty Pharma in December 2025). The stock's next hard catalysts come from PTC's own pipeline (Sephience, ST-920), not Evrysdi. Per the rubric, an approved drug with no imminent new regulatory decision scores 3-5.
Actionable Insight NEUTRAL

Evrysdi is a mature, approved drug with no upcoming binary catalysts. PTC has already monetized virtually all of its royalty interest. Investors should watch PTC's Q4 2026 earnings (likely late January/early February 2027) for Evrysdi full-year sales trends and whether the $2.5B annual sales milestone for the $150M Roche payment is approaching, but the stock's primary catalysts now lie elsewhere in PTC's pipeline.

Price Chart

Loading chart...

Executive Summary

Evrysdi (risdiplam) is an oral SMN2 splicing modifier approved since August 2020 for spinal muscular atrophy (SMA). It was discovered by PTC Therapeutics and is developed and commercialized by Roche/Genentech. PTC has fully monetized its royalty interest through a series of deals with Royalty Pharma, culminating in December 2025 when the remaining royalty was sold for $240M upfront. PTC still reports Evrysdi royalty revenue ($81.7M in Q3 2026) and retains a $150M sales milestone if annual Evrysdi sales reach $2.5B. Evrysdi is the market-leading SMA drug by sales growth, competing with Biogen's Spinraza and Novartis' Zolgensma. For PTC investors, Evrysdi is a declining financial story as the royalty has been largely monetized, and the company's value drivers have shifted to its own commercial product Sephience and pipeline assets like ST-920.

How It Works

Evrysdi is an oral, daily medicine that modifies how the SMN2 gene is spliced (read and processed) to produce more of the survival motor neuron (SMN) protein, which is deficient in spinal muscular atrophy (SMA). It is the only non-invasive disease-modifying SMA treatment, available as both an oral solution and a tablet that can be taken at home.

Trial Status

Evrysdi was initially FDA-approved in August 2020 for SMA in patients 2 months and older. The tablet formulation was approved in February 2025, and a label expansion for administration via feeding tubes was approved in February 2026. The drug is approved in over 100 countries and has been studied in the most inclusive SMA clinical trial program (FIREFISH, SUNFISH, RAINBOWFISH, JEWELFISH), including long-term follow-up data showing sustained benefit over 5 years.

The Two-Sided Case

▲ Bull Case4
Evrysdi is the fastest-growing SMA therapy, driven by oral convenience and broad age eligibility, with year-to-date sales through Q3 2026 of approximately CHF 1,470 million (roughly $1.7B), up ~30% year-over-year.
PTC retains a $150 million milestone payment from Roche if Evrysdi achieves single-year sales of $2.5 billion, providing upside optionality.
The drug continues to gain label expansions (tablet formulation Feb 2025, feeding tube administration Feb 2026), expanding the addressable patient population.
Evrysdi has long patent protection with Orange Book patents extending to at least 2035-2041, limiting generic competition risk for over a decade.
▼ Bear Case4
PTC has fully monetized its Evrysdi royalty stream, selling 100% of the royalty interest to Royalty Pharma by December 2025 for a total of approximately $1.9B across multiple transactions. The remaining royalty revenue PTC reports is a diminishing pass-through.
Evrysdi faces competition from Biogen's Spinraza (intrathecal injection) and Novartis' Zolgensma (one-time gene therapy), plus emerging pipeline therapies like Scholar Rock's apitegromab.
PTC's stock is now driven by other assets (Sephience for PKU, ST-920 for Fabry disease), making Evrysdi a less central part of the investment thesis.
Insider selling has been persistent, with director Michael Schmertzler and EVP Mark Boulding executing multiple 10b5-1 plan sales in recent months.

Upcoming Catalysts

  • No upcoming binary catalysts for Evrysdi specifically; it is a mature approved product. PTC's stock catalysts now center on Sephience (PKU) commercial ramp and the ST-920 Fabry gene therapy BLA filing.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PTC THERAPEUTICS, INC. 8-K PTCT ·Originating report

Sources · 9

Hover a chip for the title
1 ir.ptcbio.com2 fda.gov3 roche.com4 royaltypharma.com5 ir.ptcbio.com6 sec.gov7 drugpatentwatch.com8 managedhealthcareexecutive.com9 ir.ptcbio.com